Abstract
Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity. Many pretargeting approaches have been proposed, but only those using the biotin / avidin recognition system and those using bispecific anti-tumor x anti-hapten antibodies have been tested in the clinic for both immunoscintigraphy and radioimmunotherapy. Their respective advantages and drawbacks, as well as hurdles in the way of an effective therapy against solid tumors, are discussed. In the light of the encouraging results obtained so far in the clinic, pretargeting remains a most promising challenge for chemistry and biotechnology.
Keywords: pretargeting, immunoscintigraphy, radioimmunotherapy, antibodies, cancer
Current Medicinal Chemistry
Title: Recent Advances in Pretargeted Radioimmunotherapy
Volume: 12 Issue: 3
Author(s): A. Gruaz-Guyon, O. Raguin and J. Barbet
Affiliation:
Keywords: pretargeting, immunoscintigraphy, radioimmunotherapy, antibodies, cancer
Abstract: Pretargeted delivery of radionuclides is based upon bispecific immunoconjugates that bind a target tumor antigen and a small molecule carrying the active payload. This strategy is supposed to combine the advantage of antibodies to track tumor cells in vivo and of small radiolabeled molecules that clear rapidly from normal organs and minimize toxicity. Many pretargeting approaches have been proposed, but only those using the biotin / avidin recognition system and those using bispecific anti-tumor x anti-hapten antibodies have been tested in the clinic for both immunoscintigraphy and radioimmunotherapy. Their respective advantages and drawbacks, as well as hurdles in the way of an effective therapy against solid tumors, are discussed. In the light of the encouraging results obtained so far in the clinic, pretargeting remains a most promising challenge for chemistry and biotechnology.
Export Options
About this article
Cite this article as:
Gruaz-Guyon A., Raguin O. and Barbet J., Recent Advances in Pretargeted Radioimmunotherapy, Current Medicinal Chemistry 2005; 12 (3) . https://dx.doi.org/10.2174/0929867053363225
DOI https://dx.doi.org/10.2174/0929867053363225 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol in Cancer: Cellular and Mitochondrial Consequences of Proton Transport Inhibition
Current Pharmaceutical Design Metabotropic Purinergic Receptors in Lipid Membrane Microdomains
Current Medicinal Chemistry Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Current Medicinal Chemistry Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Anticancer Drug Discovery from the Marine Environment
Recent Patents on Anti-Cancer Drug Discovery Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Nanofibers: New Insights for Drug Delivery and Tissue Engineering
Current Topics in Medicinal Chemistry Glucose Transporters Regulation on Ischemic Brain: Possible Role as Therapeutic Target
Central Nervous System Agents in Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued) A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Role of Protein Tyrosine Phosphatase in Regulation of Cell Signaling Cascades Affecting Tumor Cell Growth: A Future Perspective as Anti-Cancer Drug Target
Current Pharmaceutical Biotechnology Fibroblast Growth Factor-Inducible 14: Multiple Roles in Tumor Metastasis
Current Molecular Medicine The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Annexins as Neuroprotective Agents in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued)